DALLAS, Nov. 17 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) today announced that a recommendation report was issued by ChangeWave, a research network that identifies emerging trends and companies best-positioned to capitalize in today's marketplace. The report was written by Mr. Joshua Levine, Editor of ChangeWave Investing and ChangeWave MicroCap Investor.
Advertisement
According to Mr. Levine, "Finally, with MuGard now commercialized, Access is already receiving its first royalties, and cash flow will steadily ramp up in the coming quarters. Since MuGard has pharmaceutical-type margins, it will instantly impact Access' financial situation. The increase in revenue will provide financial security for this company with an active partnering and outsourcing model and a very small $3 million-a-year burn rate."
Advertisement
Mr. Levine also cited, "Looking at its pipeline, Access is involved in discussions with potential regional and global partners for a ProLindac license covering North America and Europe, which together represent at least 80% of the overall market. The company also intends to initiate additional ProLindac Phase II combo trials globally."
"We are pleased to have Access be highlighted by ChangeWave, a well-respected research firm that has a vast audience base looking for emerging growth companies that are in the proper position to capitalize on emerging trends," stated Jeffrey Davis, Access' President & CEO.
To obtain the full report or future write-ups on Access, go to www.changewave.com and subscribe to the ChangeWave MicroCap Investor newsletter.
About ChangeWave: ChangeWave, a subsidiary of InvestorPlace Media, LLC, was founded in 2001, with the goal of creating a world-class expert research network to identify emerging trends, technologies and companies best-positioned to capitalize in today's market -- and bring it to subscribers well in advance of other available sources. ChangeWave Research leads one of the world's leading independent equities and macro-economic research organizations serving institutional and self-directed private investors.
About Access: Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
Contact: Company Contact: Investor Relations Stephen B. Thompson Donald C. Weinberger/Diana Bittner (media) Vice President, Wolfe Axelrod Weinberger Assoc. LLC Chief Financial Officer (212) 370-4500 Access Pharmaceuticals, Inc. (214) 905-5100
SOURCE Access Pharmaceuticals, Inc.
